Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT00616109 trial: what clinicians have said so far
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
- NCT00616109 ↗
- Completed
- University of Michigan Rogel Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT00616109 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT00616109 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- sunitinib
- Arms
- Maintenance Sunitinib · Experimental
- Enrollment
- 16
- Primary outcomes
- Progression Free Survival Rate
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2007
- Primary completion
- Dec 2009
- Results posted
- Yes
- Registry record
- NCT00616109 · updated Apr 21, 2014
Publications
linked from the registry- Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3. PubMed 21512407